TY  - JOUR 
AU  - Hervella-Ordoñez, Marina
AU  - Cañibano Cimas, Luis M.
AU  - Muñóz-Ruipérez, Carmen
AU  - Alonso López, Miguel A.
AU  - del Campo, MT
AU  - Marzola-Payares, Marco
AU  - Rescalvo-Santiago, Fernando
AU  - Paula-Ortiz, Miguel de
AU  - López-Pérez, Ricardo
AU  - Bravo Grande, José Lorenzo
AU  - Blanco González, María Asunción
AU  - Torre Robles, José María de la
AU  - Asmat Inostrosa, Marita
AU  - Fernández Escribano, Marina
AU  - Mirabella Villalobos, Itria
AU  - Caso Pita, María Covadonga
AU  - Fuente Martín, José María de la
AU  - Rodríguez de la Pinta, María Luisa
AU  - Borda Olivas, Jenry Ricardo
AU  - Ramírez Pérez, María Antonieta
AU  - Sánchez Arcilla, Ignacio
AU  - Sánchez Santos, José Manuel
PY  - 2021
SN  - 0264-410X
UR  - http://hdl.handle.net/10366/145221
AB  - [EN] Trial Design: An interventional, phase 4, single group assignment, without masking (open label), preventive clinical trial was carried out in health workers with biological risk in their tasks, who have been filed as non-responders to...
LA  - eng
PB  - Vaccine
KW  - Viable vaccine alternative
KW  - Conventional vaccine
KW  - Health centres dependent
KW  - Fendrix
KW  - Preventive clinical trial
KW  - Biomedical Research
KW  - Vaccines
TI  - Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines
DO  - 10.1016/j.vaccine.2020.12.006
T2  - Vaccine
VL  - 39
M2  - 554
ER  -